Munich-based startup Cellbyte is strengthening its development with seed funding of 2.4 million euros. Investors including Frontline Ventures, Y Combinator, Pace Ventures, Saras Capital, and Springboard Health Angels are backing the young company. The founders aim to simplify and accelerate complex data processes in the pharmaceutical industry with their AI-driven platform. Many market access, pricing, and HEOR teams still work with fragmented information sources. This situation means that the path of a new drug to market can take more than a year and incur high costs.
The Cellbyte platform analyzes millions of data points from clinical, pricing, regulatory, and internal sources in real time. Teams receive precise and current foundations for pricing decisions, launch strategies, and regulatory documentation. The founders emphasize that older databases from the pre-LLM era only process easily accessible data, thus lacking the depth for sophisticated processes. Cellbyte offers a networked, continuously updated database that drastically shortens time-critical workflows. According to the company, workflows that previously took months can be reduced to a fraction of that time without compromising quality.
Felix Steinbrenner, co-CEO and co-founder of Cellbyte, says:
“The success of a drug’s entire lifecycle is decided during its launch phase. To make the best decisions for market entry, insights from gigabytes of accurate, current information are required. The traction Cellbyte has achieved since its founding with some of the world’s largest pharmaceutical companies shows that the industry is ready to rethink drug launch workflows and implement faster, higher-quality, and more cost-effective processes.”
Generative AI is transforming the market
Co-CEO and co-founder Daniel Moreira adds:
“From my many years of work in life science consulting, I have witnessed countless innovations that transformed clinical development. Yet decisions in pricing and market access are still too often based on manual work and anecdotal evidence, even though information is abundant. Now generative AI is changing this, and we are proud to drive this transformation.”
Cellbyte was founded in 2024 from the combined expertise of Daniel Moreira, Felix Steinbrenner, and Samuel Moreira in pharmaceuticals, AI, and business building. With the new funding, the team plans to triple its workforce and expand its technical infrastructure to meet demand.
One of the investors, Frontline partner William McQuillan, comments:
“Cellbyte is addressing one of the pharmaceutical industry’s biggest challenges with an AI-powered strategy. Felix, Samuel, and Daniel have pursued global goals from the start, and we are proud to support them in their expansion into the US and thus accelerate patient access to new treatments.”
